TRIM31 and pancreatic neoplasm: Interestingly, the overexpression of TRIM31 mediates gemcitabine resistance via NF-κB activation, and similarly the inhibition of TRIM31 potentiates the cytotoxic potential gemcitabine both in vitro and in vivo model of pancreatic cancer cells in NF-κB dependent manner [67].